Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daraxonrasib in First-Line Metastatic Pancreatic Adenocarcinoma
NCT07491445Phase 3Recruiting
- Sponsor
- Revolution Medicines
- Start
- Mar 2026
- Primary completion
- Jun 2028
- Countries
- 16
01
Overview
A Phase 3 trial of daraxonrasib in pancreatic adenocarcinoma (PDAC), sponsored by Revolution Medicines. Started Mar 2026; status: recruiting.
02
Drugs
daraxonrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07491445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07491445.